196 related articles for article (PubMed ID: 18445855)
1. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Cassidy J; Schmoll HJ; Van Cutsem E
J Clin Oncol; 2008 May; 26(13):2226-7; author reply 2228. PubMed ID: 18445855
[No Abstract] [Full Text] [Related]
2. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Chu E; Cartwright TH
J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
[No Abstract] [Full Text] [Related]
3. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
Hochster HS
Clin Adv Hematol Oncol; 2005 May; 3(5):405-6. PubMed ID: 16167014
[No Abstract] [Full Text] [Related]
4. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Mayer RJ
J Clin Oncol; 2007 Sep; 25(27):4165-7. PubMed ID: 17709796
[No Abstract] [Full Text] [Related]
5. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Bölke E; Peiper M; Budach W
N Engl J Med; 2008 May; 358(18):1965; author reply 1965. PubMed ID: 18450611
[No Abstract] [Full Text] [Related]
8. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Tse VC; Ng WT; Lee V; Lee AW; Chua DT; Chau J; McGhee SM
BMC Cancer; 2011 Jul; 11():288. PubMed ID: 21740590
[TBL] [Abstract][Full Text] [Related]
9. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
[TBL] [Abstract][Full Text] [Related]
10. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
11. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
12. Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Pettersson K; Carlsson G; Holmberg C; Sporrong SK
Acta Oncol; 2012 Sep; 51(7):840-8. PubMed ID: 22937953
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for colorectal cancer.
Goyle S; Maraveyas A
Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
[TBL] [Abstract][Full Text] [Related]
16. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR
Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755
[TBL] [Abstract][Full Text] [Related]
17. Reader comments on the cost of cancer care.
Toftbagen C
Clin J Oncol Nurs; 2006 Feb; 10(1):15; author reply 15-6. PubMed ID: 16482722
[No Abstract] [Full Text] [Related]
18. Adjuvant therapy for stage II and III colorectal cancer.
de Gramont A; Tournigand C; André T; Larsen AK; Louvet C
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S37-40. PubMed ID: 17449351
[TBL] [Abstract][Full Text] [Related]
19. Oral Xeloda plus bi-platinu two-way combined chemotherapy in treatment of advanced gastrointestinal malignancies.
Fan L; Liu WC; Zhang YJ; Ren J; Pan BR; Liu DH; Chen Y; Yu ZC
World J Gastroenterol; 2005 Jul; 11(28):4300-4. PubMed ID: 16038024
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
